This HTML5 document contains 135 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n8http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n11http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n4http://linked.opendata.cz/resource/drugbank/company/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00836/identifier/chemspider/
n14http://linked.opendata.cz/resource/drugbank/dosage/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00836/identifier/chebi/
n9http://linked.opendata.cz/resource/drugbank/mixture/
n19http://bio2rdf.org/drugbank:
n31http://linked.opendata.cz/resource/drugbank/drug/DB00836/identifier/wikipedia/
n29http://linked.opendata.cz/resource/drugbank/drug/DB00836/identifier/pharmgkb/
admshttp://www.w3.org/ns/adms#
n24http://linked.opendata.cz/resource/drugbank/drug/DB00836/identifier/kegg-compound/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00836/identifier/bindingdb/
n30http://linked.opendata.cz/resource/drugbank/drug/DB00836/identifier/pubchem-compound/
n15http://linked.opendata.cz/resource/drugbank/patent/
n6http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n13http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n28http://www.drugs.com/cdi/
n32http://linked.opendata.cz/resource/drugbank/drug/DB00836/identifier/kegg-drug/
n27http://linked.opendata.cz/resource/drugbank/drug/DB00836/identifier/pubchem-substance/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00836/identifier/drugbank/
n17http://linked.opendata.cz/resource/drugbank/property/
n16http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
xsdhhttp://www.w3.org/2001/XMLSchema#
n12http://linked.opendata.cz/resource/atc/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00836/identifier/national-drug-code-directory/
n10http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00836
rdf:type
n3:Drug
n3:description
One of the long-acting synthetic antidiarrheals; it is not significantly absorbed from the gut, and has no effect on the adrenergic system or central nervous system, but may antagonize histamine and interfere with acetylcholine release locally. [PubChem]
n3:dosage
n14:271B49C4-363D-11E5-9242-09173F13E4C5 n14:271B49C5-363D-11E5-9242-09173F13E4C5 n14:271B49C0-363D-11E5-9242-09173F13E4C5 n14:271B49C1-363D-11E5-9242-09173F13E4C5 n14:271B49C2-363D-11E5-9242-09173F13E4C5 n14:271B49C3-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
9.1 to 14.4 hours (average 10.8 hours)
n3:indication
For the control and symptomatic relief of acute nonspecific diarrhea and of chronic diarrhea associated with inflammatory bowel disease or gastroenteritis. Also used for reducing the volume of discharge from ileostomies.
n3:manufacturer
n4:271B49B2-363D-11E5-9242-09173F13E4C5 n4:271B49B1-363D-11E5-9242-09173F13E4C5 n4:271B49B0-363D-11E5-9242-09173F13E4C5
owl:sameAs
n6:DB00836 n19:DB00836
dcterms:title
Loperamide
adms:identifier
n21:6532 n22:3818 n23:50017698 n24:C07080 n25:0378-2100-01 n26:DB00836 n27:46504591 n29:PA450262 n30:3955 n31:Loperamide n32:D08144
n3:mechanismOfAction
<i>In vitro</i> and animal studies show that Loperamide acts by slowing intestinal motility and by affecting water and electrolyte movement through the bowel. Loperamide inhibits peristaltic activity by a direct effect on the circular and longitudinal muscles of the intestinal wall. It is a non-selective calcium channel blocker and binds to opioid mu-receptors. Evidence also suggests that at higher concentrations it binds to calmodulin.
n3:packager
n4:271B49A9-363D-11E5-9242-09173F13E4C5 n4:271B49A6-363D-11E5-9242-09173F13E4C5 n4:271B49A7-363D-11E5-9242-09173F13E4C5 n4:271B49A4-363D-11E5-9242-09173F13E4C5 n4:271B49A5-363D-11E5-9242-09173F13E4C5 n4:271B49A2-363D-11E5-9242-09173F13E4C5 n4:271B49A3-363D-11E5-9242-09173F13E4C5 n4:271B49A0-363D-11E5-9242-09173F13E4C5 n4:271B49A1-363D-11E5-9242-09173F13E4C5 n4:271B499E-363D-11E5-9242-09173F13E4C5 n4:271B499F-363D-11E5-9242-09173F13E4C5 n4:271B498C-363D-11E5-9242-09173F13E4C5 n4:271B499D-363D-11E5-9242-09173F13E4C5 n4:271B498B-363D-11E5-9242-09173F13E4C5 n4:271B4987-363D-11E5-9242-09173F13E4C5 n4:271B4988-363D-11E5-9242-09173F13E4C5 n4:271B4985-363D-11E5-9242-09173F13E4C5 n4:271B4986-363D-11E5-9242-09173F13E4C5 n4:271B49AE-363D-11E5-9242-09173F13E4C5 n4:271B49AF-363D-11E5-9242-09173F13E4C5 n4:271B49AC-363D-11E5-9242-09173F13E4C5 n4:271B49AD-363D-11E5-9242-09173F13E4C5 n4:271B499A-363D-11E5-9242-09173F13E4C5 n4:271B499B-363D-11E5-9242-09173F13E4C5 n4:271B4998-363D-11E5-9242-09173F13E4C5 n4:271B4999-363D-11E5-9242-09173F13E4C5 n4:271B4996-363D-11E5-9242-09173F13E4C5 n4:271B4997-363D-11E5-9242-09173F13E4C5 n4:271B4994-363D-11E5-9242-09173F13E4C5 n4:271B4995-363D-11E5-9242-09173F13E4C5 n4:271B4992-363D-11E5-9242-09173F13E4C5 n4:271B4993-363D-11E5-9242-09173F13E4C5 n4:271B4990-363D-11E5-9242-09173F13E4C5 n4:271B4991-363D-11E5-9242-09173F13E4C5 n4:271B498E-363D-11E5-9242-09173F13E4C5 n4:271B498F-363D-11E5-9242-09173F13E4C5 n4:271B498D-363D-11E5-9242-09173F13E4C5 n4:271B499C-363D-11E5-9242-09173F13E4C5 n4:271B4989-363D-11E5-9242-09173F13E4C5 n4:271B498A-363D-11E5-9242-09173F13E4C5 n4:271B49AA-363D-11E5-9242-09173F13E4C5 n4:271B49AB-363D-11E5-9242-09173F13E4C5 n4:271B49A8-363D-11E5-9242-09173F13E4C5
n3:patent
n15:2134611
n3:routeOfElimination
Excretion of the unchanged loperamide and its metabolites mainly occurs through the feces.
n3:synonym
Loperamidum Loperamid Lopéramide Loperamida
n3:toxicity
Oral, mouse: LD<sub>50</sub> = 105 mg/kg. Symptoms of overdose include constipation, drowsiness, lethargy, and nausea.
n10:hasAHFSCode
n11:56-08-00
n3:foodInteraction
Take without regard to meals. Increase liquid intake.
n3:mixture
n9:271B4984-363D-11E5-9242-09173F13E4C5
n3:proteinBinding
97%
n3:salt
n3:synthesisReference
Tsutomu Awamura, Hisanobu Nishikawa, Toshio Inagi, "FILM PREPARATION CONTAINING LOPERAMIDE HYDROCHLORIDE." U.S. Patent US20110159058, issued June 30, 2011.
foaf:page
n8:loperamide.htm n16:imo1206.shtml n28:loperamide.html
n3:IUPAC-Name
n17:271B49CA-363D-11E5-9242-09173F13E4C5
n3:InChI
n17:271B49D0-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n17:271B49CF-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n17:271B49CC-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n17:271B49CD-363D-11E5-9242-09173F13E4C5
n3:SMILES
n17:271B49CE-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n17:271B49C8-363D-11E5-9242-09173F13E4C5 n17:271B49E0-363D-11E5-9242-09173F13E4C5
n3:logP
n17:271B49C9-363D-11E5-9242-09173F13E4C5 n17:271B49C6-363D-11E5-9242-09173F13E4C5 n17:271B49E2-363D-11E5-9242-09173F13E4C5
n3:logS
n17:271B49C7-363D-11E5-9242-09173F13E4C5
n10:hasATCCode
n12:A07DA03
n3:H-Bond-Acceptor-Count
n17:271B49D6-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n17:271B49D7-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n17:271B49D1-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n17:271B49D2-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n17:271B49D4-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n17:271B49D3-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n17:271B49D5-363D-11E5-9242-09173F13E4C5
n3:absorption
Not significantly absorbed from the gut
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
53179-11-6
n3:category
n3:containedIn
n13:271B49BA-363D-11E5-9242-09173F13E4C5 n13:271B49BB-363D-11E5-9242-09173F13E4C5 n13:271B49BE-363D-11E5-9242-09173F13E4C5 n13:271B49BF-363D-11E5-9242-09173F13E4C5 n13:271B49BC-363D-11E5-9242-09173F13E4C5 n13:271B49BD-363D-11E5-9242-09173F13E4C5 n13:271B49B9-363D-11E5-9242-09173F13E4C5 n13:271B49B7-363D-11E5-9242-09173F13E4C5 n13:271B49B8-363D-11E5-9242-09173F13E4C5 n13:271B49B5-363D-11E5-9242-09173F13E4C5 n13:271B49B6-363D-11E5-9242-09173F13E4C5 n13:271B49B3-363D-11E5-9242-09173F13E4C5 n13:271B49B4-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n17:271B49DC-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n17:271B49DE-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n17:271B49DF-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n17:271B49E1-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n17:271B49DB-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n17:271B49DA-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n17:271B49DD-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n17:271B49CB-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n17:271B49D8-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n17:271B49D9-363D-11E5-9242-09173F13E4C5